Progressive Multiple Sclerosis study: Obecabtagene autoleucel
Official title Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
ClinicalTrials.gov ID: NCT07139743
What this study is testing
What is Obecabtagene autoleucel (obe-cel)?
This is an investigational biological treatment being studied for progressive multiple sclerosis. is designed to use a patient's own immune cells, modified to target a specific protein on cells, to help manage the disease.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to see if obe‑cel is safe and to look for early signs that it might help with MS symptoms.
- Who it's for
- Adults with progressive multiple sclerosis who have tried at least two other disease‑modifying therapies and have not responded.
- What's involved
- Participants will receive a short course of chemotherapy to prepare their bodies, then a single infusion of obe‑cel. They will be closely monitored for 28 days after the infusion and then followed for up to 24 months.
- Time commitment
- The study lasts up to 24 months, with frequent visits in the first month after treatment and regular check‑ups thereafter.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 60
You may be able to join if
- Willing and able to give written informed consent for participation in the study.
- Ability and willingness to adhere to the protocol's Schedule of Activities and other requirements.
- Participants must be 18 to 60 years of age inclusive at the time of signing the informed consent form.
- A female participant is eligible to participate if she is not pregnant or breastfeeding.
- Current diagnosis of PMS.
You likely can't join if
- Any medications prohibited by the protocol.
- Highly active multiple sclerosis.
- Diagnosis of another autoimmune central nervous system condition.
- Active or uncontrolled fungal, bacterial, viral infection.
- History of malignant neoplasms unless disease-free for at least 24 months.
- History of heart, lung, kidney, liver transplant or hematopoietic stem cell transplant.
See the full eligibility criteria
- Willing and able to give written informed consent for participation in the study.
- Ability and willingness to adhere to the protocol's Schedule of Activities and other requirements.
- Participants must be 18 to 60 years of age inclusive at the time of signing the informed consent form.
- A female participant is eligible to participate if she is not pregnant or breastfeeding.
- Current diagnosis of PMS.
- Must have been treated previously with at least 2 disease-modifying therapies.
- Any medications prohibited by the protocol.
- Highly active multiple sclerosis.
- Diagnosis of another autoimmune central nervous system condition.
- Active or uncontrolled fungal, bacterial, viral infection.
- History of malignant neoplasms unless disease-free for at least 24 months.
- History of heart, lung, kidney, liver transplant or hematopoietic stem cell transplant.
The study team makes the final eligibility decision.
Where it is enrolling
- Palo Alto, California, United States
- Barcelona, Spain
- Valencia, Spain
- Cambridge, United Kingdom
- Edinburgh, United Kingdom
- London, United Kingdom
- Sheffield, United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 60 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Palo Alto, California, United States; Barcelona, Spain; Valencia, Spain; Cambridge, United Kingdom; Edinburgh, United Kingdom; London, United Kingdom and 1 more location. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.